Geniposide, an
iridoid glycoside isolated from Gardenia, has neuroprotective activities against oxidative stress and
inflammation. The present study investigated the in vivo protective effect of
geniposide on
ischemia/reperfusion-injured rats by
middle cerebral artery occlusion (MCAO), and the inhibitory effects of
geniposide and mechanisms against activation of microglial cells by
oxygen-
glucose deprivation (OGD) in vitro. Male SD rats were subjected to treatment with
geniposide at 15, 30 and 60 mg/kg immediately after MCAO.
Cerebral infarct volume and microglial cell activation were assessed following 24 h reperfusion. Cultured primary rat microglial cells were exposed to
geniposide at the concentrations of 12.5, 25 and 50 μg/mL during 4 h of OGD. The effects of
geniposide were evaluated in terms of (1) cell viability; (2) secretion of TNF-α, IL-1β,
IL-6,
IL-8 and
IL-10 into
culture media; (3) TLR4
mRNA expression; (4)
protein expression of TLR4, p-ERK1/2, p-IκB, p-p38, nuclear and cytoplasmic fraction NF-κB p65; and (5) nuclear transfer of NF-κB p65.
Geniposide reduced the
infarct volume and inhibited the activation of microglial cells in ischemic penumbra in vivo. OGD increased cell viability and release of TNF-α, IL-1β,
IL-6,
IL-8 and
IL-10, these effects were suppressed by
geniposide.
Geniposide also attenuated the increases in the OGD-induced TLR4
mRNA and
protein levels. In addition,
geniposide at 25 and 50 μg/mL downregulated the phosphorylation of ERK, IκB and p38, as well as inhibited nuclear transcriptional activity triggered via NF-κB p65 in microglial cells by OGD. In conclusion,
geniposide displays a
neuroprotective effect on
ischemia/reperfusion-injured rats in vivo and inhibits OGD-induced activation of microglial cells by attenuating inflammatory factors and NF-κB activation in vitro.